Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T96721
|
||||
Former ID |
TTDS00339
|
||||
Target Name |
Vascular endothelial growth factor
|
||||
Synonyms |
VEGF; Vascular endothelial cell growth factor
|
||||
Target Type |
Successful
|
||||
Disease | Adult primary hepatocellular carcinoma [ICD10: C22] | ||||
Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Lymphoma; Non-hodgkin's lymphoma [ICD9: 200, 202, 202.8; ICD10: C81-C86, C82-C85] | |||||
Metastatic breast cancer [ICD10: C50] | |||||
Multiple myeloma [ICD9: 203; ICD10: C90] | |||||
Non-small cell lung cancer [ICD10: C33-C34] | |||||
Non-small cell lung cancer; Metastatic colorectal cancer [ICD9:153, 154; ICD10: C33-C34, C18-C21] | |||||
Recurrent squamous cell carcinoma of the hypopharynx [ICD10: D37] | |||||
Target Validation |
T96721
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Avastin+/-Tarceva | Drug Info | Phase 3 | Non-small cell lung cancer | [551595] |
Bevacizumab + Erlotinib | Drug Info | Phase 3 | Non-small cell lung cancer; Metastatic colorectal cancer | [553819], [554242] | |
Bevacizumab + Rituximab | Drug Info | Phase 3 | Lymphoma; Non-hodgkin's lymphoma | [522045] | |
Bevacizumab + Trastuzumab | Drug Info | Phase 3 | Metastatic breast cancer | [532301] | |
Bevacizumab + Erlotinib | Drug Info | Phase 2 | Adult primary hepatocellular carcinoma | [523055], [553932], [554003], [555115], [555445], [555446] | |
Bevacizumab + Trastuzumab | Drug Info | Phase 2 | Breast cancer | [554002] | |
Bevacizumab + Erlotinib | Drug Info | Phase 1/2 | Recurrent squamous cell carcinoma of the hypopharynx | [553734] | |
AT001/r84 | Drug Info | Phase 1 | Cancer | [550216] | |
References | |||||
Ref 522045 | ClinicalTrials.gov (NCT00486759) A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma. U.S. National Institutes of Health. | ||||
Ref 523055 | ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health. | ||||
Ref 532301 | AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25. | ||||
Ref 553734 | ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | ||||
Ref 553819 | ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | ||||
Ref 553932 | ClinicalTrials.gov (NCT00287222) Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma | ||||
Ref 554002 | ClinicalTrials.gov (NCT00365365) Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer | ||||
Ref 554003 | ClinicalTrials.gov (NCT00365391) Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | ||||
Ref 554242 | ClinicalTrials.gov (NCT00598156) Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva | ||||
Ref 555115 | ClinicalTrials.gov (NCT02655536) Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.